Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Disturbances in Heart Rhythm01:28

Disturbances in Heart Rhythm

895
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
895
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

770
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
770
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

900
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
900
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

405
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
405

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of increased coronary physiology and intracoronary imaging use with downstream healthcare costs.

Cardiovascular revascularization medicine : including molecular interventions·2026
Same author

Efficacy and safety of atrial fibrillation ablation in patients with Marfan syndrome: A multicenter analysis.

Heart rhythm O2·2026
Same author

Diagnosis and Management of Loeys-Dietz Syndrome: Evidence Gaps and Future Directions.

Current cardiology reports·2026
Same author

The Role of Multimodality Imaging in Guiding Ventricular Tachycardia Ablation: An Updated Review.

Reviews in cardiovascular medicine·2026
Same author

Cardiac surgical outcomes and predictors of redo sternotomy in patients with Marfan syndrome: a retrospective multicentre cohort study.

Open heart·2026
Same author

GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated Lp(a) levels: A Multicenter retrospective study.

International journal of cardiology·2026

Related Experiment Video

Updated: Jun 3, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.3K

Advances in Atrial Fibrillation Management: A Guide for General Internists.

Hoang Nhat Pham1, Ramzi Ibrahim2, Hong Hieu Truong3

  • 1Department of Medicine, University of Arizona, Tucson, AZ 85719, USA.

Journal of Clinical Medicine
|January 8, 2025
PubMed
Summary
This summary is machine-generated.

New atrial fibrillation (AF) guidelines emphasize early detection and patient-centered care. General internists can improve patient outcomes by adopting these updated strategies for managing this common cardiac arrhythmia.

Keywords:
atrial fibrillationguidelineslifestyle modificationmanagementrisk factor modification

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.5K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

19.6K

Related Experiment Videos

Last Updated: Jun 3, 2025

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.3K
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

83.5K
Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

19.6K

Area of Science:

  • Cardiology
  • Internal Medicine
  • Public Health

Background:

  • Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia in the US, affecting millions and projected to double by 2030.
  • AF substantially elevates the risk of stroke and other cardiovascular events, contributing to significant morbidity and mortality.
  • Current management paradigms are evolving to address the growing burden of AF.

Purpose of the Study:

  • To review the 2023 ACC/AHA/ACCP/HRS guidelines for atrial fibrillation diagnosis and management.
  • To provide general internists with insights into the updated, patient-centered approach to AF care.
  • To highlight the shift from duration-based classification to a comprehensive risk-factor-focused strategy.

Main Methods:

  • Analysis of the 2023 ACC/AHA/ACCP/HRS guidelines.
  • Examination of the novel AF classification system emphasizing early detection and intervention.
  • Review of recommendations for multidisciplinary care models and primary care provider roles.

Main Results:

  • The guidelines introduce a paradigm shift towards a patient-centered approach, moving beyond duration-based AF classification.
  • A novel classification system prioritizes early detection, risk factor assessment, and tailored lifestyle modifications.
  • Emphasis is placed on a multidisciplinary care model, empowering primary care providers in proactive AF management.

Conclusions:

  • The updated guidelines offer a comprehensive framework for managing atrial fibrillation effectively.
  • General internists are pivotal in implementing risk factor management and lifestyle interventions for AF prevention and care.
  • Adoption of these guidelines can enhance patient outcomes and navigate the evolving landscape of AF management.